COVID-19 Implications for Biopharma

Jonathan Kfoury

Implications for biopharma

COVID-19 impact on biopharma

reshaping the biopharma ecosystem

ways reshaping the biopharma ecosystem

Biopharma is on front line in combating the crisis

Alliances involving biopharma are being formed

Digital companies are uniquely positioned

M&A to remain active in biopharma

impacting every function in biopharma

closer look at functions

Current challenges with clinical trials

Biopharma supply chain

Commercial/medical functions

Uncertain cash flows and valuations

We encourage biopharma execs

Connect with us

Disclaimer

Related Insights

Healthcare Services • Executive Insights

Asia-Pacific 2021 Hospital Priorities: Settling Into the New Normal

March 11, 2021

L.E.K. Consulting conducted the 2021 APAC Hospital Priority Survey with 411 hospital executives across both public and private hospitals in countries1…

Life Sciences & Pharma •

Trends in Pharma Asset Licensing and Deal Terms: A Survey of Key Decision-Makers

March 19, 2021

In this Executive Insights, we describe some key drivers of asset value, as well as areas of alignment on and divergence from deal expectations between…

Life Sciences & Pharma • Video / Webinar

L.E.K. Look Forward: Advanced Therapies, Bioprocessing and AI in Life Sciences

December 2, 2021

Life Sciences & Pharma • Video / Webinar

How Have Hospitals Across APAC Adapted to the Impact of COVID-19?

April 8, 2021

L.E.K. Consulting’s survey of hospital executives at private and public hospitals in the Asia Pacific region reveals three key themes.

Life Sciences & Pharma • Executive Insights

Preparedness, Policy And Patients – Learning From The Pandemic

May 19, 2021

We must ask what we have learnt from our recent experiences that can be deployed to help accelerate approaches to fighting other, similarly devastating,…

Life Sciences & Pharma • Video / Webinar

Omnichannel Engagement for Pharma Companies in APAC

November 18, 2021